Nuclein is a medical device company that is developing next-generation molecular diagnostic systems. Nuclein’s lead product, DASHTM, is a quantitative PCR system designed to automatically identify viral and bacterial agents within 15 minutes.The device is designed to detect nucleic acids of target pathogens from various sample types and automates the process from sample preparation to PCR amplification. The speed, ease of use, and portability of DASH, offers an important advancement in molecular diagnostics with potential applications of bringing molecular testing to the wider community in the US and throughout the world.

Nuclein

Founded: 2017
Location: Austin, TX
Employee range: 11 - 50
Funding: $14M Mar 2021

Short description:

Drug notes:

Long description:

Jobs: